|

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

RECRUITINGPhase 1/2Sponsored by Peking University First Hospital
Actively Recruiting
PhasePhase 1/2
SponsorPeking University First Hospital
Started2025-06-01
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07508852

Summary

This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults.
* Histologically confirmed small cell lung cancer (SCLC).
* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.

Exclusion Criteria:

* Pregnancy.
* Breastfeeding.
* Acute psychiatric disorders.
* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
* Inability to complete the study procedures as anticipated.
* Prior therapy targeting DLL3.

Conditions7

CancerLung CancerSCLCSCLC, Limited StageSCLC,Extensive StageSmall Cell Lung CancerSmall Cell Lung Cancer (SCLC)

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.